Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Gerald S. Bloomfield, Pamela S. Douglas(Duke University), Jessica Tuan(Yale University), Heather J. Ribaudo(Cancer Research And Biostatistics), Carl J. Fichtenbaum(Cancer Research And Biostatistics), Sarah M Chu(Harvard University), Craig A. Sponseller, Thomas Campbell(University of Colorado Anschutz Medical Campus), Gerald Pierone(Orthopaedic Center of Vero Beach), Steven Grinspoon(Massachusetts General Hospital), Michael T. Lu(Cancer Research And Biostatistics), Carlos Malvestutto(The Ohio State University Wexner Medical Center), Frank S. Rhame(University of Minnesota), Marissa R Diggs(Harvard University), Judith S. Currier(University of California, Los Angeles), Sara McCallum(Cancer Research And Biostatistics), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), Maya Watanabe(Cancer Research And Biostatistics), Aya Awwad(Harvard University), Markella V. Zanni(Harvard University), Sophia Zhao(Massachusetts General Hospital), Michelle Cespedes(Icahn School of Medicine at Mount Sinai)
Cited by 2
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
|The Journal of Clinical Endocrinology & Metabolism|2007|1.6k